Journal
TRENDS IN PHARMACOLOGICAL SCIENCES
Volume 31, Issue 5, Pages 206-211Publisher
ELSEVIER SCIENCE LONDON
DOI: 10.1016/j.tips.2010.02.001
Keywords
-
Categories
Funding
- National Institutes of Health [RO1 AI045297, U19AI082608, T32 AI 07001-33]
- Merck Research Laboratories
- NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007001, U19AI082608, R01AI045297, R34AI084553] Funding Source: NIH RePORTER
- NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH085597] Funding Source: NIH RePORTER
Ask authors/readers for more resources
Given the scope of the human immunodeficiency virus (HIV) pandemic, millions of people will need of chronic antiretroviral therapy (ART) for decades into the future. It is hoped that progress in prevention of HIV infection can be made, but there have been few successes in this effort thus far. ART also presents formidable problems. Therefore, research must continue on improvements in prevention and treatment, but future HIV research should now also seek to develop temporally contained therapies capable of eradicating HIV infection. This review will explore what is known about the mechanisms that restrain HIV expression and result in persistent, latent proviral infection, and what these mechanisms tell us about potential approaches towards eradication of HIV infection.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available